FDA Declines Review of Moderna’s mRNA Flu Shot
Feb. 10, 2026 — The U.S. Food and Drug Administration informed Moderna on Tuesday that it would not open a review of the company’s mRNA influenza vaccine candidate, a decision the company said followed concerns about the trial’s comparator. Moderna enrolled roughly 41,000 adults aged 50 and older and reported that its shot outperformed GSK’s … Read more